Company Tibet Duo Rui Pharmaceutical Co., Ltd.

301075

CNE100004RW5

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 2026-06-26			5-day change	1st Jan Change
59.21 ^CNY	-6.87%		-11.77%	-0.77%

04-28	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
04-23	Tibet Duo Rui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Business description: Tibet Duo Rui Pharmaceutical Co., Ltd.

Tibet Duo Rui Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical preparations, intermediates and active pharmaceutical ingredients. The Company mainly has self-produced products such as Sodium Acetate Ringer Injection and agent products such as Amoxicillin Sodium and Clavulanate Potassium for Injection. The Company's products mainly include liquid therapy, emergency medication, pediatric medication, psychiatric medication, and analgesic medication. The Company mainly operates its businesses in the domestic market.

Number of employees: 497

Sales by Activity: Tibet Duo Rui Pharmaceutical Co., Ltd.

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
Active Pharmaceutical Ingredient (api)	-	-	-	10.32M	-
Pharmaceutical Distribution and Others	-	103M	99.61M	38M	-
Preparations	-	298M	235M	187M	-
Others	64.26M	-	-	5.51M	-
Sodium Acetate Ringer's Injection	465M	-	-	-	-

See all business segments

Geographical breakdown of sales: Tibet Duo Rui Pharmaceutical Co., Ltd.

Fiscal Period: December	2021 (CNY)	2022 (CNY)	2023 (CNY)	2024 (CNY)	2025 (CNY)
China	530M	401M	334M	241M	-

See all geographic segments

Executive Committee: Tibet Duo Rui Pharmaceutical Co., Ltd.

Manager	Title	Age	Since
Yong Deng CEO	Chief Executive Officer	60	2018-11-30
Chao Li DFI	Director of Finance/CFO	47	2017-04-30
Fen Jin DFI	Director of Finance/CFO	46	2017-11-30
Ying Liu IRC	Investor Relations Contact	39	-
Bo Ao PRN	Corporate Officer/Principal	40	2022-03-22

See TIBET DUO RUI PHARMACEUTICAL CO., LTD. governance

Composition of the Board of Directors: Tibet Duo Rui Pharmaceutical Co., Ltd.

Director	Title	Age	Since
Ying Fei Liu BRD	Director/Board Member	48	2020-02-20
Yong Deng CHM	Chairman	60	2017-11-30
Shao Zhong Zhang BRD	Director/Board Member	70	2020-02-20
Qin Deng BRD	Director/Board Member	58	2020-02-20
Fei Qi BRD	Director/Board Member	49	2020-02-20
Fen Jin BRD	Director/Board Member	46	2022-04-14
Yun Guo Wang BRD	Director/Board Member	54	2022-04-14

Composition of the Board of Directors

Shareholders: Tibet Duo Rui Pharmaceutical Co., Ltd.

Name	Stocks	%	Valuation
China Asset Management Co., Ltd. 0.0394 %	10,800	0.0394 %	119 017 ¥
Orient Fund Management Co., Ltd. 0.0263 %	7,200	0.0263 %	79 345 ¥
CCB Principal Asset Management Co., Ltd. 0.002188 %	600	0.002188 %	6 612 ¥

List of TIBET DUO RUI PHARMACEUTICAL CO., LTD. shareholders

Company details: Tibet Duo Rui Pharmaceutical Co., Ltd.

Tibet Duo Rui Pharmaceutical Co., Ltd.

3/F, Building 1, Biomedical Park

854000, Changdu

http://www.duoruiyy.com

address Tibet Duo Rui Pharmaceutical Co., Ltd.(301075)

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
TIBET DUO RUI PHARMACEUTICAL CO., LTD.	-6.87%	-11.77%	+104.81%	+157.10%	687M
ELI LILLY AND COMPANY	+7.13%	+9.97%	+55.80%	+160.09%	1,077B
JOHNSON & JOHNSON	+3.99%	+11.50%	+67.09%	+55.96%	613B
ABBVIE INC.	+4.20%	+17.03%	+38.97%	+91.06%	448B
ROCHE HOLDING AG	+0.99%	+4.85%	+28.17%	+23.89%	332B
ASTRAZENECA PLC	+1.82%	+8.19%	+40.04%	+27.95%	293B
NOVARTIS AG	+0.22%	+6.75%	+31.30%	+42.34%	286B
NOVO NORDISK A/S	+0.73%	+8.53%	-27.33%	-39.55%	215B
AMGEN INC.	+1.56%	+6.14%	+29.30%	+60.97%	193B
GILEAD SCIENCES, INC.	+3.26%	+3.33%	+15.55%	+68.24%	159B
Average	+1.70%	+6.26%	+38.37%	+64.80%	361.68B
Weighted average by Cap.	+3.84%	+8.92%	+41.77%	+80.18%